ATOSSA THERAPEUTICS, INC. Secures Nasdaq Listing: What Investors Need to Know

ATOSSA THERAPEUTICS, INC. recently announced a critical update regarding its standing on the Nasdaq stock exchange. This summary breaks down the news and its implications for investors.

Nasdaq Listing Compliance Restored

ATOSSA THERAPEUTICS, INC. announced on February 17, 2026, it successfully regained compliance with Nasdaq's minimum bid price requirement. This ensures the company's common stock continues trading on The Nasdaq Capital Market, removing a significant concern for investors.

Nasdaq confirmed the company met this requirement by maintaining a closing bid price of $1.00 or more for at least 10 consecutive trading days, a milestone achieved on February 13, 2026.

Why This Happened and Why It Matters

Nasdaq rules require a company's stock price to remain above $1.00 per share for continued listing. Atossa Therapeutics initially received a notice from Nasdaq on February 21, 2025, after its stock price fell below $1.00 for 30 consecutive business days. Nasdaq first granted the company until August 20, 2025, to regain compliance, then extended the deadline to February 17, 2026.

Regaining compliance is crucial for several reasons:

• Market Access and Liquidity: This ensures the stock remains easily tradable on a major exchange, providing investors with liquidity to buy and sell shares. Delisting would typically shift the stock to over-the-counter (OTC) markets, which are less liquid and often less transparent.
• Investor Confidence: A Nasdaq listing signals stability and adherence to regulatory standards. This can bolster investor confidence and attract institutional investors, who often avoid non-exchange-listed stocks.
• Capital Raising: Access to major capital markets is vital for a clinical-stage biotechnology company like Atossa. It allows them to raise funds for drug development through public offerings.

Beyond Compliance: Atossa's Core Business and Strategy

While this news addresses a critical listing issue, investors should also understand Atossa Therapeutics' core mission. The company is a clinical-stage biopharmaceutical firm developing novel therapeutics for oncology and infectious diseases.

Its primary drug candidates include:

• Endoxifen: An oral selective estrogen receptor modulator (SERM) in Phase 2 clinical trials for breast cancer treatment, including breast density reduction and other indications.
• AT-H201: A nasal spray in early-stage clinical development for COVID-19 and other respiratory diseases.

The company's strategy focuses on advancing these drug candidates through clinical trials, seeking regulatory approvals, and ultimately bringing them to market. Maintaining its Nasdaq listing ensures Atossa retains a platform to fund and communicate these efforts.

Financial Context and Key Risks

Developing new medicines is a capital-intensive endeavor. While this 8-K filing specifically addresses listing compliance, investors should always review Atossa's latest financial reports (10-K and 10-Q filings). These reports provide insight into the company's cash position, burn rate, and funding needs for ongoing clinical trials. The ability to raise capital directly depends on its continued Nasdaq listing.

Investing in clinical-stage biotech companies carries significant risks beyond listing compliance, including:

• Clinical Trial Outcomes: The success or failure of drug candidates across various trial phases.
• Regulatory Approval: Obtaining necessary approvals from health authorities like the FDA.
• Competition: The emergence of competing therapies.
• Intellectual Property: Protecting its drug patents and technologies.
• Further Dilution: The potential need for future equity offerings, which could dilute existing shareholders.

What Investors Should Monitor Next

With the delisting threat removed, Atossa can now fully focus on its primary objective: advancing its drug pipeline. Investors should closely monitor:

• Clinical Trial Progress: Updates on patient enrollment, interim data, and final results for Endoxifen and AT-H201.
• Regulatory Milestones: Announcements regarding interactions with regulatory bodies or potential fast-track designations.
• Financial Health: Quarterly and annual reports for insights into its cash runway and funding strategies.
• Strategic Partnerships: Collaborations or licensing agreements that could accelerate development or provide non-dilutive funding.

This Nasdaq compliance news is a positive foundational step, ensuring the company remains on a prominent trading platform. However, investors' long-term value will ultimately depend on the successful development and commercialization of its therapeutic candidates. As always, conduct thorough due diligence and consider your risk tolerance when investing in biotechnology companies.